荣昌生物制药（烟台）股份有限公司近日向上海证券交易所科创板递交招股书并已获批准，拟募资40亿元。金杜律师事务所担任发行人律师。

荣昌生物成立于2008年，总部位于山东烟台，专注于抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。据财经媒体消息，2020年11月，荣昌生物在港交所上市，并以5.9亿美元创造了2020年全球生物技术IPO募资最高纪录。

根据招股书显示，金杜团队的经办律师为合伙人高怡敏、孙及、李强。

华泰联合证券在此次上市项目中担任保荐人。

KWM advising HK-listed RemeGen’s planned $626mln secondary listing in STAR Market

King & Wood Mallesons is advising RemeGen, a Hong-Kong listed biomedicine maker, on its planned $626 million secondary listing in STAR Market.

Established in 2008, the Yantai-headquartered RemeGen focuses on making therapeutic antibody medicines such as ADC and antibody fusion protein. In November 2020, the company completed its $590 million IPO in Hong Kong, which created the highest global biotech IPO fundraising record in 2020.

According to the company’s prospectus, the KWM team is led by partners Gao Yimin, Sun Ji, and Li Qiang.

Huatai United Securities serves as the sponsor.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.